FindTrial
Sign In

To assess LDL-C control (less than 55 mg/dL) in patients with ACS with current available treatments.

Hypercholesterolemia in Acute Coronary Syndrome Patients in India - A Retrospective Real- World Evidence Study - ACS Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/05/042446
Enrollment
558
Registered
2022-05-11
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I249- Acute ischemic heart disease, unspecified

Interventions

Intervention1: Not Applicable: Not Applicable Control Intervention1: Not Applicable: Not Applicable

Sponsors

Novartis Healthcare Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients aged >18 years. 2. Patients with ACS event [One or more of the following: ST-segment-elevation myocardial infarction or left bundle branch block myocardial infarction (STEMI/LBBB MI), a non-ST-segment-elevation myocardial infarction (NSTEMI), or UA with or without PCI/ CABG. 3. Lipid profile data available at index date/15 days of index date and at least once at 3, 6, 9, 12 months post-index date ACS event.

Exclusion criteria

Exclusion criteria: Patients meeting any of the following criteria will not be included in the study: 1. Incomplete paper-based records/EMRs data. 2. Non-availability of paper-based records/EMRs for 12 monthsâ?? time point post index date ACS event.

Design outcomes

Primary

MeasureTime frame
To assess LDL-C control (less Than 55 mg/dL) in patients with ACS with current available treatmentsTimepoint: Time Frame: Baseline, Months 3, 6, 9, and 12—

Secondary

MeasureTime frame
In patients with ACS with current available treatments A. To Assess LDL-C control (Less Than 30, Less Than 50, Less than 70, Less Than 100 mg/dL) B. To assess Lp(a) testing and control C. To study the change in lipid profile parameters D. To assess treatment pattern of statin positive or negative, other lipid lowering drugs, statin intolerance E. To assess tolerability-of LLTs F. To assess demographic profile, clinical characteristics, and concomitant medicationsTimepoint: A. Proportion of ACS patients achieving LDL-C goal at 3, 6, 9, and 12 Months after index date of CS event B. Proportion of ACS patients who underwent Lp(a) testing C. Change in lipid profile parameters in 3, 6, 9, and 12 months D. treatment pattern of statin, other lipid lowering drugs, statin intolerance at 3, 6, 9, 12 months E. Proportion of ACS patients who reported AE F. Clinical characteristics of ACS patient and various concomitant medications at baseline—

Countries

India

Contacts

Public ContactDr Venugopal Madhusudhana

Sekhmet Technologies Pvt. Ltd

venugopal@thb.co.in7738371973

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026